Search Results

Processa Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City.

Processa Pharmaceuticals, Inc. today announced that it has named Steven Cha, M.D. as Senior Vice President of Clinical Research.

Processa Pharmaceuticals, Inc. announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference.

Processa Pharmaceuticals, Inc. announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.

Processa Pharmaceuticals, Inc. announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial which defined the Maximum Tolerated Dose and Recommended Phase 2 Dose Range for Next Generation Capecitabine administered to patients with Stage III or IV gastrointestinal tract cancer.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), announces that George Ng, Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2024.